No black box warning on record for Quinapril And Hydrochlorothiazide 10/12.5

As of the latest FDA labeling reviewed, Quinapril And Hydrochlorothiazide 10/12.5 (QUINAPRIL AND HYDROCHLOROTHIAZIDE 10/12.5) does not carry a black box warning. Standard warnings and precautions still apply — see the full Quinapril And Hydrochlorothiazide 10/12.5 medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin converting inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including quinapril) may be subject to a variety of adverse reactions, some of them serious. Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue,

No black box warning on record for Quinapril And Hydrochlorothiazide 10/12.5

Other warnings & precautions

WARNINGS Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin converting inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including quinapril) may be subject to a variety of adverse reactions, some of them serious. Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue,

Quinapril And Hydrochlorothiazide 10/12.5 Black Box Warning

No black box warning on record for Quinapril And Hydrochlorothiazide 10/12.5

Other warnings & precautions

Quinapril And Hydrochlorothiazide 10/12.5 Black Box Warning

No black box warning on record for Quinapril And Hydrochlorothiazide 10/12.5

Other warnings & precautions